NLRP3 and diabetes mellitus: At the same time, zafirlukast and bromocriptine treatment could suppress the expression of NLRP3 in DG (Figure 7A, 7B) and CA1 (Supplementary Figure 1) regions, and suppressed the expression of GOLPH3 in DG (Figure 8A, 8B) and CA1 (Supplementary Figure 3) regions, indicating that STZ induced diabetes might cause neuroinflammation in hippocampus regions, and zafirlukast combined with bromocriptine could ameliorate diabetes induced neuroinflammation by suppressing the expression of NLRP3 and Golph3.